TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20500867

Group type: EXPERIMENTAL
Intervention: Mandatory second look surgery with CRS and HIPEC (intraperitoneal oxaliplatin with concurrent systemic 5-fluorouracil and leucovorin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (routine surveillance)
Number of subjects: 100
Study: 18629590

Group type: EXPERIMENTAL
Intervention: High SES in low-deductible plans
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Low SES in high-deductible plans
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Colonoscopy recommendation for high SES in low-deductible plans
Number of subjects: 528

Group type: COMPARATOR
Intervention: Inappropriate screening recommendations
Number of subjects: 528
Study: 16817817

Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (1 mg 17beta oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12821734

Group type: EXPERIMENTAL
Intervention: IV ceftriaxone for 28 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10819315

Group type: EXPERIMENTAL
Intervention: Chromium picolinate, 1,000 microg/d for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 19
Study: 8774024

Group type: EXPERIMENTAL
Intervention: Tapping with the forefinger of the nonpreferred hand throughout the task
Number of subjects: 66

Group type: COMPARATOR
Intervention: No tapping (control group)
Number of subjects: 66
Study: 1628373

Group type: EXPERIMENTAL
Intervention: Single dose of 125 mg MPN
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two doses of 125 mg MPN
Number of subjects: 20
Study: 6432200

Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl, twice daily infusions
Number of subjects: 32

Group type: COMPARATOR
Intervention: 4% dextrose and saline infusion (control)
Number of subjects: 32
Study: 31122211

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil (DR)
Number of subjects: 80
Study: 29182791

Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg/day for 7 days plus standardized topical treatment (moderately strong steroid and moisturizer)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standardized topical treatment alone (control group)
Number of subjects: 39
Study: 27067305

Group type: EXPERIMENTAL
Intervention: Brief quitline facilitation intervention (5-minute intervention with warm handoff or faxed referral to a national quitline provider)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Brief cessation advice (control group)
Number of subjects: 600
Study: 24762381

Group type: EXPERIMENTAL
Intervention: Aqueous oxygen peroxide (AOP) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sterile water placebo
Number of subjects: 61
Study: 22352336

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Number of subjects: 65

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) 300/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both DRV/r and ATV/r
Number of subjects: 65
Study: 19546163

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study: 17686453

Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (Ca)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (F)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (Ca) with fluoride dentifrice (F)
Number of subjects: 10
Study: 16129089

Group type: EXPERIMENTAL
Intervention: Web-based component of a nutrition and physical activity behavioral intervention
Number of subjects: 194
Study: 12392804

Group type: EXPERIMENTAL
Intervention: Brief motivational psychotherapy
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Series of treatment-related videos
Number of subjects: 279

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 279
Study: 11817338

Group type: EXPERIMENTAL
Intervention: Adenosine rinse (0.12 mM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (without adenosine)
Number of subjects: 43
Study: 7672157

Group type: EXPERIMENTAL
Intervention: 600 mg/d of vitamin E
Number of subjects: 30

Group type: COMPARATOR
Intervention: Identical placebo tablets
Number of subjects: 30
Study: 2123160

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate (n = 21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin acetate (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of both routes (IN vs SC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Correlation with initial fibroid size
Number of subjects: 40

Group type: COMPARATOR
Intervention: Correlation with patient age
Number of subjects: 40
Study: 464030

Group type: EXPERIMENTAL
Intervention: Myofeedback therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 31522234

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 475

Group type: COMPARATOR
Intervention: PSA/DRE strategy
Number of subjects: 475
Study: 30629728

Group type: EXPERIMENTAL
Intervention: Active intranasal neurostimulation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham control intranasal stimulation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 58
Study: 28153666

Group type: EXPERIMENTAL
Intervention: Glue (Dermabond; Ethicon)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Monofilament sutures (Monocryl; Ethicon)
Number of subjects: 104
Study: 26474867

Group type: EXPERIMENTAL
Intervention: Participatory intervention consisting of three workshops aimed at reducing excessive physical workloads.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Technical measurements (EMG, accelerometers, video recordings) before and after the intervention.
Number of subjects: 80
Study: 24148211

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no adenotonsillectomy)
Number of subjects: 57
Study: 21255134

Group type: EXPERIMENTAL
Intervention: ximelagatran (higher doses)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: ximelagatran (lower and higher doses)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: ximelagatran
Number of subjects: 518

Group type: COMPARATOR
Intervention: aspirin alone
Number of subjects: 518
Study: 19184083

Group type: EXPERIMENTAL
Intervention: Noncircular chainring system (ROT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Noncircular chainring system (ROT+)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional chainring system (CON)
Number of subjects: 15
Study: 17696035

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) with infrared laser (780 nm, 70 mW, 10 s, 89.7 J/cm2), applied twice a week for four weeks.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group (control) using identical probes, one active and one that does not emit radiation.
Number of subjects: 48
Study: 15262483

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 0
Study: 11442705

Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (no RAI implementation)
Number of subjects: 348
Study: 9876394

Group type: EXPERIMENTAL
Intervention: Schuss view
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standing on homolateral foot
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Extended knee view
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Schuss view after 1 year
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Extended knee view after 1 year
Number of subjects: 32
Study: 7975698

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 448
Study: 2681451

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d. for three months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin during run-out period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin during double-blind period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo during double-blind period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin during run-out phase
Number of subjects: 20
Study: 799991

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 80 mg/day
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Flurbiprofen or Ibuprofen
Number of subjects: 195
Study: 31150356

Group type: EXPERIMENTAL
Intervention: Curcuminoid extract 250 mg, four times a day on postoperative days 1-3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no curcuminoids)
Number of subjects: 60
Study: 29224209

Group type: EXPERIMENTAL
Intervention: 9-month course of daily isoniazid (9H)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 12-week course of weekly isoniazid and rifapentine (3HP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3HP (12-week course of weekly isoniazid and rifapentine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 9H (9-month course of daily isoniazid)
Number of subjects: 80
Study: 25560547

Group type: EXPERIMENTAL
Intervention: E-learning course on breast imaging for radiographers
Number of subjects: 107
Study: 22922073

Group type: EXPERIMENTAL
Intervention: Video group (VG)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Voice feedback group (VFG)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Combined group (CG)
Number of subjects: 213
Study: 21125277

Group type: EXPERIMENTAL
Intervention: Aprepitant 125/80 mg group (125 mg on day 1 and 80 mg on days 2-5) and dexamethasone (6 mg on day 1 and 4 mg on days 2 and 3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aprepitant 40/25 mg group (40 mg on day 1 and 25 mg on days 2-5) and dexamethasone (8 mg on day 1 and 6 mg on days 2 and 3)
Number of subjects: 20
Study: 19275475

Group type: EXPERIMENTAL
Intervention: Vidnar group (mobile narrative on a mobile phone during daily train trip)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nonar group (only video content on a mobile phone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MP3 group (only audio content on an MP3 player)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no-intervention condition)
Number of subjects: 120
Study: 16951398

Group type: EXPERIMENTAL
Intervention: Neomycin (660 mg three times daily for three consecutive days, starting 2 days before chemotherapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 62
Study: 12548410

Group type: EXPERIMENTAL
Intervention: Drainage plus fistulotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 200
Study: 11460274

Group type: EXPERIMENTAL
Intervention: Tablet fluoride (0.25 mg F daily)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Liquid fluoride (0.25 mg F daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no fluoride)
Number of subjects: 115
Study: 9327783

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg/d)
Number of subjects: 15
Study: 8269562

Group type: COMPARATOR
Intervention: Plain bupivacaine (n = 31)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine with hyaluronidase (n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (n = 29)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bupivacaine with both epinephrine and hyaluronidase (n = 30)
Number of subjects: 120
Study: 3980272

Group type: EXPERIMENTAL
Intervention: Continuous radiation + 5‐FU (16 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Split‐course radiation + 5‐FU (14 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maintenance MeCCNU + 5‐FU chemotherapy (21 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous-course (12 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Split-course (9 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall treatment (30 patients)
Number of subjects: 30
Study: 30420282

Group type: COMPARATOR
Intervention: NDCI (Non-Depressed and Cognitively Intact)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LLD (Late-Life Depression)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MCI (Mild Cognitive Impairment)
Number of subjects: 23
Study: 29431141

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 280
Study: 27105046

Group type: EXPERIMENTAL
Intervention: Intensive therapy group (rosuvastatin 10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy group (rosuvastatin 2.5 mg)
Number of subjects: 30
Study: 25513813

Group type: EXPERIMENTAL
Intervention: mHealth momentary assessment Routine Outcome Monitoring (mROM)
Number of subjects: 34
Study: 22337533

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (ever vs. never)
Number of subjects: 507
Study: 20450635

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-SBT (no spontaneous breathing trial)
Number of subjects: 67
Study: 18539795

Group type: EXPERIMENTAL
Intervention: Probiotic group (10 log(10) CFU of Lactobacillus salivarius CECT5713 and Lactobacillus gasseri CECT5714 for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (excipient only)
Number of subjects: 20
Study: 11174502

Group type: EXPERIMENTAL
Intervention: Prolonged antenatal betamethasone therapy (three or more sets of weekly injections given in 21.3% of cases, and > or =4 sets in 12.3% of cases)
Number of subjects: 414
Study: 9886900

Group type: EXPERIMENTAL
Intervention: Pulse Wave Analysis (PWA) for measuring Pulse Wave Velocity (PWV)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pulse Wave Analysis (PWA) for measuring Augmentation Index (AIx)
Number of subjects: 57
Study: 8039473

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 3180724

Group type: EXPERIMENTAL
Intervention: One day orientation letter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Letter prompt received one day before appointment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Letter prompt received three days before appointment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Orientation letter received one day before appointment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Orientation letter received three days before appointment
Number of subjects: 150
Study: 31661946

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - treadmill walking session (5 × (3 min at 70% HRR + 3 min at 30% HRR))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) - treadmill walking session (30 min at 50% HRR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON) - rest session
Number of subjects: 15
Study: 28368456

Group type: EXPERIMENTAL
Intervention: RSV immunoprophylaxis
Number of subjects: 3263

Group type: COMPARATOR
Intervention: RSV infection
Number of subjects: 3263
Study: 25596202

Group type: EXPERIMENTAL
Intervention: Synflorix at 2, 4, 6 months of age
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Prevenar13 at 2, 4, 6 months of age
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Synflorix at 1, 2, 4 months plus Prevenar13 at 6 months of age
Number of subjects: 425

Group type: COMPARATOR
Intervention: All groups (Synflorix, Prevenar13, and investigational schedule)
Number of subjects: 425
Study: 23223772

Group type: EXPERIMENTAL
Intervention: Automated administration of propofol and remifentanil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Manual administration of propofol and remifentanil
Number of subjects: 31
Study: 21810630

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg daily dose)
Number of subjects: 69
Study: 19538532

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 179
Study: 16896862

Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 17

Group type: COMPARATOR
Intervention: IFD CPAP
Number of subjects: 17
Study: 15303780

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 142
Study: 11433556

Group type: EXPERIMENTAL
Intervention: Web-based data entry system for recording project activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geographic information systems (GISs) for developing visual maps of project targets
Number of subjects: 0
Study: 9282827

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 microM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 16
Study: 8054933

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30295516

Group type: EXPERIMENTAL
Intervention: Executive Function Enhancement Program (EFEP) applied three times a week for six weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 111
Study: 30339954

Group type: EXPERIMENTAL
Intervention: Restraint use
Number of subjects: 6397
Study: 28543183

Group type: EXPERIMENTAL
Intervention: YH4808 (≥200 mg/d)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: YH4808 (twice-daily regimen)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: YH4808
Number of subjects: 123

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 25287702

Group type: EXPERIMENTAL
Intervention: IVUS-guided group (38 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-IVUS group (42 patients)
Number of subjects: 80
Study: 23261366

Group type: EXPERIMENTAL
Intervention: Imunoglukan P4H® syrup (with pleuran-β-glucan from Pleurotus ostreatus and vitamin C)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (vitamin C only)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Imunoglukan P4H® syrup
Number of subjects: 175
Study: 21593010

Group type: EXPERIMENTAL
Intervention: TCARE® protocol
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 19258951

Group type: EXPERIMENTAL
Intervention: Cisplatin/paclitaxel or carboplatin/paclitaxel (first-line chemotherapy)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Her‐2/neu overexpression (2+/3+)
Number of subjects: 783
Study: 16293352

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg/day as a single dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15462105

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 46
Study: 11737509

Group type: EXPERIMENTAL
Intervention: 0.04% PHMB mouthrinse (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine aqueous solution (C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Commercially available mouthrinse (Skinsept mucosa) diluted to 0.12% chlorhexidine (D)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative control placebo rinse (10% ethanol, flavour) (B)
Number of subjects: 16
Study: 9240726

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) or HRT and parathyroid hormone peptide 1-38
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dpd (deoxypyridinoline)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dpd
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroxyproline
Number of subjects: 19
Study: 8326078

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 3717020

Group type: EXPERIMENTAL
Intervention: High-dose intravenous heparin to maintain the whole blood clotting time between 15 and 20 minutes, and commenced warfarin therapy within 48 hours.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin and warfarin therapy if the peak creatine kinase level was more than 1,000 U/liter.
Number of subjects: 82
Study: 31628019

Group type: EXPERIMENTAL
Intervention: IIS training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving IIS training program)
Number of subjects: 0
Study: 29573513

Group type: EXPERIMENTAL
Intervention: Positive psychology Internet-based intervention (PPI; n = 74)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Waiting list control condition (WLC; n = 48)
Number of subjects: 122
Study: 27560668

Group type: EXPERIMENTAL
Intervention: Internal conus design implants (ICI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: External hex design implants (EXI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both ICI and EXI implants
Number of subjects: 39
Study: 24354839

Group type: EXPERIMENTAL
Intervention: Text message reminders (5 weekly messages and 2 appointment reminders)
Number of subjects: 1187
Study: 22348921

Group type: EXPERIMENTAL
Intervention: BUP plus HereToHelp™ (HTH) patient support program
Number of subjects: 1426

Group type: COMPARATOR
Intervention: BUP alone (standard care)
Number of subjects: 1426

Group type: EXPERIMENTAL
Intervention: Compliant patients (BUP + HTH)
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Non-compliant patients (BUP)
Number of subjects: 1426
Study: 20590606

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 10